Literature DB >> 20101644

Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock.

Vincent Zoete1, Aurélien Grosdidier, Michel Cuendet, Olivier Michielin.   

Abstract

Protein-ligand docking has made important progress during the last decade and has become a powerful tool for drug development, opening the way to virtual high throughput screening and in silico structure-based ligand design. Despite the flattering picture that has been drawn, recent publications have shown that the docking problem is far from being solved, and that more developments are still needed to achieve high successful prediction rates and accuracy. Introducing an accurate description of the solvation effect upon binding is thought to be essential to achieve this goal. In particular, EADock uses the Generalized Born Molecular Volume 2 (GBMV2) solvent model, which has been shown to reproduce accurately the desolvation energies calculated by solving the Poisson equation. Here, the implementation of the Fast Analytical Continuum Treatment of Solvation (FACTS) as an implicit solvation model in small molecules docking calculations has been assessed using the EADock docking program. Our results strongly support the use of FACTS for docking. The success rates of EADock/FACTS and EADock/GBMV2 are similar, i.e. around 75% for local docking and 65% for blind docking. However, these results come at a much lower computational cost: FACTS is 10 times faster than GBMV2 in calculating the total electrostatic energy, and allows a speed up of EADock by a factor of 4. This study also supports the EADock development strategy relying on the CHARMM package for energy calculations, which enables straightforward implementation and testing of the latest developments in the field of Molecular Modeling.

Mesh:

Substances:

Year:  2010        PMID: 20101644     DOI: 10.1002/jmr.1012

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  10 in total

1.  Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Ute F Röhrig; Somi Reddy Majjigapu; Pierre Vogel; Aline Reynaud; Florence Pojer; Nahzli Dilek; Patrick Reichenbach; Kelly Ascenção; Melita Irving; George Coukos; Olivier Michielin; Vincent Zoete
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  Small molecule antivirulents targeting the iron-regulated heme oxygenase (HemO) of P. aeruginosa.

Authors:  Kellie Hom; Geoffrey A Heinzl; Suntara Eakanunkul; Pedro E M Lopes; Fengtian Xue; Alexander D MacKerell; Angela Wilks
Journal:  J Med Chem       Date:  2013-03-01       Impact factor: 7.446

3.  Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1.

Authors:  Asma Bourafai-Aziez; Mohammed Benabderrahmane; Hippolyte Paysant; Louis-Bastien Weiswald; Laurent Poulain; Ludovic Carlier; Delphine Ravault; Marie Jouanne; Gaël Coadou; Hassan Oulyadi; Anne-Sophie Voisin-Chiret; Jana Sopková-de Oliveira Santos; Muriel Sebban
Journal:  Drug Des Devel Ther       Date:  2021-12-15       Impact factor: 4.162

4.  Biological Evaluation and Docking Studies of Synthetic Oleanane-type Triterpenoids.

Authors:  Mariano Ortega-Muñoz; Fernando Rodríguez-Serrano; Eduardo De Los Reyes-Berbel; Nuria Mut-Salud; Fernando Hernández-Mateo; Andrea Rodríguez-López; José M Garrido; F Javier López-Jaramillo; Francisco Santoyo-González
Journal:  ACS Omega       Date:  2018-09-20

5.  Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.

Authors:  Anamika Basu; Anasua Sarkar; Ujjwal Maulik
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

6.  Using ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of polo-like kinase 1.

Authors:  Yaw Sing Tan; Paweł Śledź; Steffen Lang; Christopher J Stubbs; David R Spring; Chris Abell; Robert B Best
Journal:  Angew Chem Int Ed Engl       Date:  2012-09-07       Impact factor: 15.336

7.  Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection.

Authors:  Mehabaw G Derebe; Clare M Zlatkov; Sureka Gattu; Kelly A Ruhn; Shipra Vaishnava; Gretchen E Diehl; John B MacMillan; Noelle S Williams; Lora V Hooper
Journal:  Elife       Date:  2014-07-29       Impact factor: 8.140

8.  Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides.

Authors:  Malgorzata Kucinska; Maria-Dolores Giron; Hanna Piotrowska; Natalia Lisiak; Walter H Granig; Francisco-Javier Lopez-Jaramillo; Rafael Salto; Marek Murias; Thomas Erker
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

9.  Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape.

Authors:  Vincent Zoete; Thierry Schuepbach; Christophe Bovigny; Prasad Chaskar; Antoine Daina; Ute F Röhrig; Olivier Michielin
Journal:  J Comput Chem       Date:  2015-11-12       Impact factor: 3.376

Review 10.  Application of the SwissDrugDesign Online Resources in Virtual Screening.

Authors:  Antoine Daina; Vincent Zoete
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.